DATE
Regeneron Licenses Hansoh’s GLP-1/GIP Obesity Drug to Compete with Zepbound
Regeneron; Hansoh Pharmaceuticals; HS-20094; GLP-1/GIP receptor agonist; obesity drug; Zepbound; Eli Lilly; obesity treatment; licensing deal; biopharma
Bicara’s Ficerafusp Alfa Shows 46% 2-Year Survival Rate for Head and Neck Cancer Subset at ASCO 2025
ASCO 2025; Bicara Therapeutics; ficerafusp alfa; head and neck cancer; PD-L1; overall survival; antibody therapy; Keytruda; tumor shrinkage
Exit Strategy: Biopharma Professionals Consider Opportunities Outside Industry and US
biopharma talent; job market trends; industry transition; employment outside US; biopharma survey 2025; life sciences employment; biotech careers; pharmaceutical industry
FDA Expects ‘Timely Availability’ of Covid Shots as Advisors Update Formula Recommendation
FDA; Covid-19; vaccine; formula update; timely availability; advisory committee; JN.1-lineage; KP.2 strain; 2025-2026
Fierce Biotech Layoff Tracker 2025: 10x Genomics cuts 8% of global workforce; NGM sheds 75% of staff
NGM, Genomics, Fierce, 8, Generalized, Staff, 75%, 2025
FDA Delays Continue as Regulator Misses Review Date for GSKs Nucala
United States Food and Drug Administration, Nucala, Chronic Obstructive Airway Disease, GSK ‘s, Target, delays, PDUFA
Vinay Prasads FDA Appointment Anything but Status Quo
United States Food and Drug Administration, Appointments, Vaccines, Prasad, Prasad ‘s, Anything, Status Quo
Citing tariffs, Illumina slashes guidance, confirms SEC’s Grail investigation is closed
Illumina, SEC, Acquisition (action), Evaluation, divestiture, Grail
FDA eyes full AI integration by June as Makary touts genAI pilot success
United States Food and Drug Administration, Aortic Valve Insufficiency, DNA Integration, Artificial Intelligence, Makary, June
FDA Vaccine Advisory Committee to Determine 2025-2026 COVID-19 Vaccine Formulation
COVID-19 vaccines, FDA advisory committee, strain selection, 2025-2026 formula, vaccine updates, VRBPAC meeting